Mon. 20 May 2024, 1:59am ET
Benzinga
News
- 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normalization at 12 Months -
- Reduction in Patient-Reported Pruritus (Itching) was Rapid and Durable in Patients with Moderate to Severe Symptoms -
- Positive Interim Results are Highly Consistent with Results from the Phase 3 RESPONSE Study of Seladelpar -